For the treatment of basal cell carcinoma, there are several methods available, including surgery, medications, and others. The rising frequency of skin cancers, as well as product approval for the treatment of basal cell carcinoma, are projected to fuel market expansion throughout the forecast period. Increased R&D spending by major companies, organisations, governments, and others is likely to contribute in the expansion of the worldwide basal cell carcinoma market during the forecast period. The primary challenges impeding the growth of the worldwide basal cell carcinoma market are high treatment costs, side effects of therapy, medication approval times that are too long, and delays in obtaining medical conditions.
According to Coherent Market Insights, the global Basal Cell Carcinoma Market is estimated to be valued at US$ 6,721.4 million in 2021 and is expected to exhibit a CAGR of 7.9% during the forecast period (2021-2028).
Market Leaders in the Basal Cell Carcinoma Industry:
1. Merck & Co., Inc.
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey. On November 2022, Merck to Acquire Imago BioSciences, Inc. Acquisition expands Merck’s growing hematology portfolio
2. Sun Pharmaceutical Industries Ltd.
Sun Pharmaceutical Industries Limited, a generic pharmaceutical company, develops, manufactures, and markets branded and generic formulations and active pharmaceutical ingredients (APIs) in India and internationally. The company was founded in 1983 and is based in Mumbai, India. On December 2016, Sun Pharma announced to acquire oncology product from Novartis for $175 mn
3. Novartis AG.
The company was incorporated in 1996 and is headquartered in Basel, Switzerland. Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. On March 2022, Novartis signs initial agreement with Carisma Therapeutics for the manufacturing of HER 2 targeted CAR-M cell therapy. Novartis in December, 2022 announced the European Commission (EC) approved Pluvicto® (INN: lutetium (177Lu) vipivotide tetraxetan), a targeted radioligand therapy.
4. Bausch & Lomb Incorporated.
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The company was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc.
5. Perrigo Company plc
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland
6. Taro Pharmaceutical Industries Ltd.
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company was founded in 1950 and is based in Haifa, Israel. Taro Pharmaceutical Industries Ltd. is a subsidiary of Alkaloida Chemical Company Exclusive Group Ltd.
7. Provectus Biopharmaceuticals, Inc.
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennesse
8. F. Hoffmann-La Roche Ltd
Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Switzerland, Germany, the United States, and internationally. The company offers pharmaceutical products in the therapeutic areas of oncology, neuroscience, infectious diseases, immunology, hemophilia, ophthalmology, dermatology, respiratory, anemia, inflammatory and autoimmune, and transplantation. Roche Holding AG was founded in 1896 and is headquartered in Basel, Switzerland. On September 2022, Roche to acquire biopharma firm Good Therapeutics for $250m. Good Therapeutics focuses on the development of PD-1-regulated IL-2 drugs that are based on innovative conditionally active drug technology.
9. Sanofi
Sanofi, together with its subsidiaries, engages in the research, development, manufacture, and marketing of therapeutic solutions and was founded in 1973. The company is headquartered in Paris, France and is operational in 100 plus countries. in September 2021, Sanofi to acquire Amunix immuno-oncology pipeline with next generation Conditionally Activated Biologics.
*Definition-Basal cell carcinoma (BCC) is an uncontrolled development of basal cells in the lower epidermis. It does not spread to other body areas, but in rare cases, it might metastasis and become life-threatening; yet, it can penetrate deep into the skin and bones.
